Explore stories from Atlantic Canada.
LONDON/COPENHAGEN - Global brewers AB InBev and Carlsberg this week played down concerns among some investors that demand for weight-loss drugs may lead to a sharp drop in beer drinking.
"Two years down the road and that conversation is gone," he said in an interview after AB InBev's results on Tuesday, adding that forecasts showed beer drinking would rise. Both CEOs said their portfolios include low-calorie and low-carbohydrate beers, while they also have significant businesses in markets where obesity is less of an issue than in those where demand for weight-loss drugs is exploding.
These were originally developed to treat type 2 diabetes, but in addition to controlling blood sugar levels, they affect hunger signals to the brain and slow the rate at which a person's stomach empties, making them feel full for longer. Nevertheless, some investors are worried about the potential impact on brewers if such drugs reduce overall consumption.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Why brewers aren't worried about Wegovy users drinking less beerExplore stories from Atlantic Canada.
Lire la suite »
Lufthansa upbeat on travel demand as Q3 beats estimatesExplore stories from Atlantic Canada.
Lire la suite »
Zalando cuts 2023 sales forecast as demand stays weakExplore stories from Atlantic Canada.
Lire la suite »
Analysis-Bruised Treasury bulls see glimmer of hope after Fed meeting, smaller issuanceExplore stories from Atlantic Canada.
Lire la suite »